Literature DB >> 1770531

Watson syndrome: is it a subtype of type 1 neurofibromatosis?

J E Allanson1, M Upadhyaya, G H Watson, M Partington, A MacKenzie, D Lahey, H MacLeod, M Sarfarazi, W Broadhead, P S Harper.   

Abstract

Over 20 years ago, Watson described three families with a condition characterised by pulmonary valvular stenosis, café au lait patches, and dull intelligence. Short stature is an additional feature of this autosomal dominant condition. A fourth family with Watson syndrome has since been reported. We have had the opportunity to review members of three of these four families. The clinical phenotype of Watson syndrome has been expanded to include relative macrocephaly and Lisch nodules in the majority of affected subjects, and neurofibromas in one-third of family members. Because the additional clinical findings enhance the similarity between Watson syndrome and neurofibromatosis 1, molecular linkage studies have been performed using probes flanking the NF1 gene on chromosome 17. Probe HHH202 showed the tightest linkage to Watson syndrome with a maximum lod score of 3.59 at phi = 0.0 (95% confidence limits of phi = 0.0-0.15). This suggests either that Watson syndrome and neurofibromatosis 1 are allelic, or that there is a series of contiguous genes for pulmonary stenosis, neurocutaneous anomalies, short stature, and mental retardation on 17q.

Entities:  

Mesh:

Year:  1991        PMID: 1770531      PMCID: PMC1017110          DOI: 10.1136/jmg.28.11.752

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  19 in total

1.  Neurofibromatosis I: predicting the relation of gene structure to gene function.

Authors:  J G Hall; J E Allanson
Journal:  Am J Med Genet       Date:  1991-01

2.  Noonan phenotype associated with neurofibromatosis.

Authors:  J E Allanson; J G Hall; M I Van Allen
Journal:  Am J Med Genet       Date:  1985-07

3.  Refined physical and genetic mapping of the NF1 region on chromosome 17.

Authors:  P R Fain; D E Goldgar; M R Wallace; F S Collins; E Wright; K Nguyen; D F Barker
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

4.  Close flanking markers for neurofibromatosis type I (NF1).

Authors:  M Upadhyaya; M Sarfarazi; S M Huson; W Broadhead; A Fryer; P S Harper
Journal:  Am J Hum Genet       Date:  1989-01       Impact factor: 11.025

5.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

6.  Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene.

Authors:  B R Seizinger; G A Rouleau; L J Ozelius; A H Lane; A G Faryniarz; M V Chao; S Huson; B R Korf; D M Parry; M A Pericak-Vance
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

7.  Pulmonary stenosis, café-au-lait spots, and dull intelligence.

Authors:  G H Watson
Journal:  Arch Dis Child       Date:  1967-06       Impact factor: 3.791

8.  Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17.

Authors:  D Barker; E Wright; K Nguyen; L Cannon; P Fain; D Goldgar; D T Bishop; J Carey; B Baty; J Kivlin
Journal:  Science       Date:  1987-05-29       Impact factor: 47.728

Review 9.  Cardiac abnormalities in neurofibromatosis.

Authors:  A E Lin; K L Garver
Journal:  Neurofibromatosis       Date:  1988

10.  Multipoint linkage analysis in neurofibromatosis type I: an international collaboration.

Authors:  D E Goldgar; P Green; D M Parry; J J Mulvihill
Journal:  Am J Hum Genet       Date:  1989-01       Impact factor: 11.025

View more
  17 in total

1.  Multiple lentigines syndrome (LEOPARD syndrome or progressive cardiomyopathic lentiginosis).

Authors:  B D Coppin; I K Temple
Journal:  J Med Genet       Date:  1997-07       Impact factor: 6.318

2.  Familial neurofibromatosis type 1 associated with an overgrowth syndrome resembling Weaver syndrome.

Authors:  C J van Asperen; W C Overweg-Plandsoen; M H Cnossen; D A van Tijn; R C Hennekam
Journal:  J Med Genet       Date:  1998-04       Impact factor: 6.318

Review 3.  The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis.

Authors:  A J Bauer; C A Stratakis
Journal:  J Med Genet       Date:  2005-06-15       Impact factor: 6.318

Review 4.  Clinical and genetic patterns of neurofibromatosis 1 and 2.

Authors:  N K Ragge
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

5.  SPRED 1 mutations in a neurofibromatosis clinic.

Authors:  Talia M Muram-Zborovski; David A Stevenson; David H Viskochil; David C Dries; Andrew R Wilson
Journal:  J Child Neurol       Date:  2010-02-22       Impact factor: 1.987

6.  Surgical management of coronary artery stenosis and peripheral artery occlusive disease of the lower extremity in a patient with neurofibromatosis: report of a case.

Authors:  Sureyya Talay; Ozgur Dag; Sevilay Ozmen; Bilgehan Erkut
Journal:  Surg Today       Date:  2011-05-01       Impact factor: 2.549

7.  Genotype, malleotype, phenotype, and randomness: lessons from neurofibromatosis-1 (NF-1)

Authors:  V M Riccardi
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

8.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

9.  Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a family with features of Watson syndrome and Noonan syndrome.

Authors:  M Tassabehji; T Strachan; M Sharland; A Colley; D Donnai; R Harris; N Thakker
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

10.  Vaginal rhabdomyosarcoma in a patient with Noonan syndrome.

Authors:  S Khan; H McDowell; M Upadhyaya; A Fryer
Journal:  J Med Genet       Date:  1995-09       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.